Skip to main content

Table 2 Mitochondrial dysfunction and pathway of UPRmt in carcinoma cells

From: Mitochondrial dysfunction, UPRmt signaling, and targeted therapy in metastasis tumor

Carcinoma cells Mechanism of UPRmt activation Type of axis of activation References
Lung, breast, glioma cells HSP60, HSP10 stress protein CHOP [23, 24]
Glioblastoma, melanoma, prostate carcinoma cells Gene expression of Egr-1, BCL-2, and MCL1 CHOP/ATF [39]
Lung, Pancreatic, Breast, Glioma ATF-5 CHOP [40,41,42]
Breast cancer PARP inhibition, NRF1 with SIRT7 CHOP/SIRT3 [45, 46]
Hepatic, gastrointestinal, breast carcinoma Alteration in the mtDNA copy CHOP/SIRT3/PINK [49,50,51,52]
Breast Carcinoma ROS production through ND6 gene mutation, upregulation of VEGF PINK/JNK/HIF-α stabilization [55]
Breast cancer Defect in mitochondrial gene complex I SIRT3/CHOP [56]
Oral, breast cancer NQO1 deficiency,4977 gene deletion SOD/NRF1 [57,58,59,60]
Metastatic cells Downregulation of NDUFV1 NRF1 [61]
Breast cancer mtDNA mutation CHOP/SOD/NRF1 [64]
Lung adenocarcinoma mtDNA ND6 gene mutation CHOP/SOD/NRF1 [65]
Renal, neuroblastoma, glioma FH, SDH, IDH enzyme mutation CHOP/NRF1 [66,67,68]
Head, neck, oral, breast Downregulation of OGG1-2a SIRT3 [69, 70]
Breast, Renal and Pancreatic carcinoma PINK1/BCl-2, BNIp3/NIX overexpression SIRT3/CHOP/NRF1 [71]
Hepatocellular carcinoma cells ROS production NRF2/PGC 1a/JNK [73,74,75]
Fibrosarcoma (mesenchymal tumor) Calcium dysfunction, Inhibition of NF-κB, Ros production CHOP/EGR1/JNK/MAPK [76, 77]
Breast carcinoma cells OMI/HTRA2,NRF1 SIRT3 [78, 79]
Fibrosarcoma, colorectal adenocarcinoma Knockdown of ATF4, ATF4 expression inhibition through GCN2 activation CHOP/SIRT3 [81, 82]
Glioblastoma, pancreatic cancer Inhibition of ATF5 CHOP [84]
Head, neck cancer SIRT3/FOXO3a/SOD2 CHOP/SIRT3 [85]
Myeloid leukemia Inhibition of Bcl2, knockdown of SDHB NFR1/2 [86]
Breast cancer ROS production NFR1/2/CHOP [10, 87]
Breast cancer Depletion of OMA1 increased gene expression ki67 CHOP/NFR1/PINK [88]
Myeloid leukemia metastatic cancer Inhibition of ClpP CHOP [89, 90]
Breast cancer Overexpression of Her2 CHOP [91]
Breast cancer Inhibition of JNK2 CHOP [34]
Bone carcinoma ND3 mutation CHOP/SIRT3 [92]
Breast carcinoma ROS production, SOD1/2 SIRT3 [93]
Glioblastoma BNIP3 upregulation CHOP/SIRT3/NFR1/2 [94]
Lung carcinoma Elevated fascin CHOP [96]
Breast Knockdown of BRCA1/2 SOD/NFR1 [97, 98]
Glioblastoma Downregulation of PINK, HIF-1α stabilization CHOP/PINK/NRF [99]
Breast, pancreatic cancer Knockdown of BNIP3 CHOP/NRF1/SOD [100,101,102]
Breast, neck, colorectal, head carcinoma Upregulation CAIX, HIF 1-α stabilization CHOP/SIRT3 [103, 104]
Gastric, breast, colorectal carcinoma ROS production, HIF 1-α stabilization SIRT3 [105]
Pancreatic ductal adenocarcinoma ROS production, HIF 1-α deletion PINK1/Parkin [106]
Ovarian, lung, colorectal carcinoma cells BNIP3/NIX downregulates SPHK1 CHOP/SIRT3 [107, 108]
Breast cancer Overexpression of MCU Calcium/CHOP [109, 110]
Liver cancer lining Knockdown of PDK1 CHOP/NRF1/2 [111]
Hepatocellular carcinoma Upregulation of DRp1, mitochondrial fission CHOP/NRF1 [112]
Renal carcinoma cells 2-HG, de-methylation of histone CHOP/PINK [117,118,119]
Renal and colorectal carcinoma cells Overexpression of FGF21, GDF15 CHOP/NFR1 [121, 122]